Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema

Simple Summary Lymphedema is a common complication of cancer, and patients with lymphedema have substantially decreased quality of life and suffer from lifelong symptoms. This study aimed to examine the effect of inhibition of Th2 inflammation in lymphedema by using QBX258, a combination of IL4/13 neutralizing antibodies. QBX258 treatment increased quality of life and reduced pathologic changes in skin including hyperkeratosis, cytokine production, fibrosis and immune cell recruitment. In conclusion, this study suggested that immunotherapy against IL4/13 improved patients' daily life which might be related with reduced pathological skin changes. Recent studies suggest that Th2 cells play a key role in the pathology of secondary lymphedema by elaborating cytokines such as IL4 and IL13. The aim of this study was to test the efficacy of QBX258, a monoclonal IL4/IL13 neutralizing antibody, in women with breast cancer-related lymphedema (BCRL). We enrolled nine women with unilateral stage I/II BCRL and treated them once monthly with intravenous infusions of QBX258 for 4 months. We measured limb volumes, bioimpedance, and skin tonometry, and analyzed the quality of life (QOL) using a validated lymphedema questionnaire (Upper Limb Lymphedema 27, ULL-27) before treatment, immediately after treatment, and 4 months following treatment withdrawal. We also obtained 5 mm skin biopsies from the normal and lymphedematous limbs before and after treatment. Treatment was well-tolerated; however, one patient with a history of cellulitis developed cellulitis during the trial and was excluded from further analysis. We found no differences in limb volumes or bioimpedance measurements after drug treatment. However, QBX258 treatment improved skin stiffness (p < 0.001) and improved QOL measurements (Physical p < 0.05, Social p = 0.01). These improvements returned to baseline after treatment withdrawal. Histologically, treatment decreased epidermal thickness, the number of proliferating keratinocytes, type III collagen deposition, infiltration of mast cells, and the expression of Th2-inducing cytokines in the lymphedematous skin. Our limited study suggests that immunotherapy against Th2 cytokines may improve skin changes and QOL of women with BCRL. This treatment appears to be less effective for decreasing limb volumes; however, additional studies are needed.

Automated summary

The study aimed to examine the effect of inhibiting Th2 inflammation in lymphedema by using QBX258, a combination of IL4/13 neutralizing antibodies, and found that it improved quality of life and reduced pathological skin changes in women with breast cancer-related lymphedema. Treatment with QBX258 showed improvements in skin stiffness and quality of life measurements, particularly in physical and social aspects, with histological evidence of decreased epidermal changes and cytokine expression in lymphedematous skin.